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ABSTRACT 
Dietary nitrate supplementation enhances sea level performance and may ameliorate hypoxemia at high altitude. 
However, nitrate may exacerbate acute mountain sickness (AMS), specifically headache. This study investigated 
the effect of nitrate supplementation on AMS symptoms and exercise responses with 6h hypoxia. Twenty 
recreationally-active men (mean(SD): age 22(4) years, V̇O2max 51(6) mL·min-1·kg-1) completed this randomized 
double-blinded placebo-controlled crossover study. Twelve participants were classified as AMS- based on 
Environmental Symptom Questionnaire (AMS-C) score <0.7 in both trials, and five participants were classified 
as AMS+ based on AMS-C score ≥0.7 on placebo. Five days nitrate supplementation (70mL beetroot juice 
containing ~6.4mmol nitrate daily) increased plasma NO metabolites by 182µM compared to placebo but did not 
reduce AMS or improve exercise performance. After 4h hypoxia (FIO2=0.124) nitrate increased AMS-C and 
headache severity (visual analogue scale (VAS); whole sample ∆10[1,20] mm; p=0.03) compared to placebo. In 
addition, after 5h hypoxia, nitrate increased sense of effort during submaximal exercise (∆7[-1,14]; p=0.07). In 
AMS- nitrate did not alter headache or sense of effort. In contrast, in AMS+ nitrate increased headache severity 
(∆26[-3,56] mm; p=0.07), sense of effort (∆14[1,28]; p=0.04), oxygen consumption, ventilation, and mean arterial 
pressure during submaximal exercise. On the next day, in a separate acute hypoxic exercise test (FIO2=0.141), 
nitrate did not improve time to exhaustion at 80% hypoxic V̇O2max. In conclusion, dietary nitrate increases AMS 
and sense of effort during exercise, particularly in those who experienced AMS. Dietary nitrate is therefore not 
recommended as an AMS prophylactic or ergogenic aid non-acclimatized individuals at altitude.  
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NEW AND NOTEWORTHY 
This is the first study to identify that the popular dietary nitrate supplement (beetroot) does not reduce acute 
mountain sickness (AMS) or improve exercise performance during 6 h hypoxia. The consumption of nitrate in 
those susceptible to AMS exacerbates AMS symptoms (headache) and sense of effort, and raises oxygen cost, 
ventilation, and blood pressure during walking exercise in 6 h hypoxia. These data question the suitability of 
nitrate supplementation during altitude travel in non-acclimatized people.  
INTRODUCTION 
Many people engage in altitude travel for work and leisure, with 300 million overnight stays in alpine regions 
each year (5) and hundreds of thousands of individuals traveling to other high altitude regions such as the 
Himalayas and Kilimanjaro (17). Approximately half of those that visit high altitude suffer from illnesses such as 
acute mountain sickness (AMS) (6). AMS can lead to high altitude cerebral edema (HACE) which if left untreated 
can be fatal (19). High altitude exposure also reduces exercise capacity (16). Finding interventions to counteract 
hypoxemia, the root-cause of these negative effects, is therefore important. 
 
Nitric oxide (NO) is a potent signaling molecule that modulates human physiological function via its role in the 
regulation of blood flow, muscle contractility and mitochondrial respiration (44). NO can be produced via the 
oxygen (O2)-dependent oxidation of L-arginine with the help of NO synthase (NOS) enzymes (31). However, it 
is now clear that NO can also be generated by the serial reduction of nitrate to nitrite and then NO (12). An 
increase in NO bioavailability has been observed after the consumption of dietary inorganic nitrate (49) and has 
been associated at sea level with a reduction in resting blood pressure (43), increased skeletal muscle blood flow 
(14), and enhanced exercise performance (21). Importantly, the reduction of nitrite to NO is increased in 
environments of low O2 tension, and therefore dietary nitrate consumption may be a particularly effective method 
to increase NO bioavailability at altitude. During acute exposure to hypoxia (≤ 2 h), nitrate supplementation has 
been shown to improve peripheral and muscle oxygenation during rest and exercise (33), and improve muscle 
energetics (46), lower the O2 cost of submaximal exercise (24), and enhance exercise performance in some (e.g. 
(33, 42)) but not all (e.g. (2, 10)) studies. NO may also improve diffusion capacity within the lung, and enhance 
O2 delivery (15), potentially ameliorating the root cause of AMS (hypoxemia). Because of these proposed 
beneficial physiological and exercise responses, some have recommended dietary nitrate for altitude travel (4, 
37), with a recent study concluding its use is safe and feasible at altitude (20). 
 
However, nitrate supplementation may be harmful during hypoxia. Dietary nitrate may increase AMS by elevating 
headache. Not only the cardinal symptom of AMS, it has been suggested that high-altitude headache contributes 
to the accompanying AMS symptoms of gastrointestinal symptoms, fatigue, dizziness, lightheadedness, and poor 
sleep (27). A growing body of data supports the proposed pathophysiology of high-altitude headache as a result 
of arterial dilation causing elevated cerebral blood volume and intracranial pressure. This leads to increased 
arterial and intracranial pressure transmission, trigeminovascular sensitization, and pain sensation (27). Given that 
NO is implicated in hypoxia-induced vasodilation (35), and directly stimulates the trigeminovascular system (3), 
supplementing with nitrate may exacerbate high-altitude headache pathophysiology. However, to date no 
laboratory studies have been completed to investigate the effects of dietary nitrate on AMS. Resolving the efficacy 
and safety of this dietary intervention, particularly in reference to the cerebral component of AMS, is of clinical 
and timely importance. In addition, the effect of dietary nitrate consumption on exercise responses during longer-
duration hypoxic exposures (>2 h) is unknown. Since the physiological stimulus of exercise may increase AMS 
severity in hypoxia (11, 38), the effects of nitrate on exercise responses, whether positive or negative, could 
potentially alter nitrate’s effect on AMS symptoms. Given that individuals travelling to high altitude will engage 
in exercise, it is important to investigate the effects of nitrate under conditions of exercise in hypoxia. In addition, 
AMS is a condition that is greatly affected by individual susceptibility (48). It is possible that nitrate may 
exacerbate AMS pathophysiology and symptoms in individuals who experience AMS, but have beneficial 
physiological and exercise performance effects in individuals who do not suffer AMS. 
 
The primary aim of the present double-blind placebo-controlled crossover study was to determine the effect of 
five days of dietary nitrate supplementation on high-altitude headache and AMS symptom severity with a 6 h 
exposure to hypoxia. We hypothesized five days of dietary nitrate supplementation would decrease high-altitude 
headache and AMS symptom severity with a 6 h exposure to hypoxia. Secondary aims of the present study were 
to explore: the effect of five days dietary nitrate supplementation on submaximal exercise responses during 6 h 
hypoxia; and the interaction of AMS (AMS present or absent) and nitrate supplementation on high-altitude 
headache severity and submaximal exercise responses during 6 h hypoxia. In addition, due to equivocal findings 
in the literature (e.g. (10, 33)), we also determined the effect of six days dietary nitrate supplementation on exercise 
performance in acute hypoxia.  
METHODS 
Participants 
Twenty recreationally-active men were recruited into the study (mean (SD); age, 22 (4) years; height, 180 (10) 
cm; body mass, 79 (11) kg; V̇O2max, 51 (6) ml·kg-1·min-1). Eleven participants (45%) had previously travelled to 
high altitude (≥ 2500 m), and of these 11 participants, 2 (18%) reported previous AMS, and none had a history of 
HAPE or HACE. Participants had not travelled to altitude (≥ 1500 m) in the preceding six months, and had no 
medical contraindications to maximal exercise testing. All participants provided written informed consent. Ethical 
approval was granted by the Ethics Committee of the School of Sport, Health, and Exercise Sciences at Bangor 
University, and the study was registered on www.clinicaltrials.gov (trial ID: NCT03101904). 
 
Study design 
The study followed a double-blinded placebo-controlled crossover design. Normoxic (FIO2 = 0.209; sea level) 
and hypoxic (FIO2 = 0.141; equivalent 3225 m) maximal exercise tests were conducted at baseline. Participants 
then completed two six-day supplementation periods, separated by a minimum ten-day washout. On day five of 
each supplementation period, a 6 h hypoxic exposure (FIO2 = 0.124; equivalent 4219 m) was conducted to assess 
AMS and responses to submaximal exercise. On day six, a time to exhaustion test was conducted at 80% V̇O2max 
reserve in acute hypoxia (FIO2 = 0.141; equivalent 3225 m) to assess exercise performance. An overview of the 
protocol is depicted in Figure 1. 
 
Supplementation 
Participants were randomly assigned to receive six days of inorganic nitrate or placebo supplementation, separated 
by a minimum ten-day washout. Supplementation consisted of a daily nitrate-rich concentrated beetroot juice shot 
(nitrate; 70 mL/day containing ~6.4mmol NO3-; Beet It Sport, James White drinks Ltd, Ipswich, UK) or a nitrate-
depleted concentrated beetroot juice shot (placebo; 70 mL/day containing ~0.003 mmol NO3-; James White drinks 
Ltd, Ipswich, UK) that was identical in appearance, taste, and texture. Placebo shots were created by passing the 
NO3- rich concentrated beetroot juice through a Purolite A520E NO3- selective ion exchange resin before 
pasteurization (26). Supplements were ingested 2.5 h before any experimental tests, and at the same time each day 
throughout both supplementation periods. Participants were phoned or texted to remind them to ingest the 
supplement and were asked to confirm ingestion by phone or return text. 
 
To isolate nutritional effects of the intervention, participants avoided high NO3- food and drink throughout the 
study, and diet and physical activity was matched before each trial, confirmed by food and exercise diaries. 
Participants also abstained from using antibacterial mouthwashes as this has previously shown to lessen the 
reduction of NO3− to NO2− by commensal bacteria within the oral cavity (18). 
 
Before (day 0) and on day five (in hypoxia) and day six (pre-hypoxia) of each supplementation phase, venous 
blood samples were collected into lithium heparin-coated 6 mL vacutainers (BD Vacutainer tubes; Becton, 
Dickinson and Company: New Jersey), immediately centrifuged at 4000 rpm and 4°C for 7 min before the plasma 
was extracted and stored at -80°C for later analysis of plasma NO metabolites (nitrate + nitrite [NOx]). To confirm 
participants were blind to the supplementation they were receiving and that the placebo was successful, a 
manipulation check was conducted after each supplementation was completed, by asking participants to guess 
what intervention they had received (possible responses were “beetroot”, “placebo”, or “don’t know”). 
 
Procedures 
Maximal aerobic capacity (V̇O2max)  
All exercise tests consisted of loaded walking whilst carrying a 15 kg rucksack on a motorized treadmill (H-P-
Cosmos, Sports & Medical GmbH; Nussdorf-Traunstein: Germany). At baseline, participants completed an 
incremental exercise test to exhaustion with simultaneous online pulmonary gas analysis (Cortex Metalyzer, 
Biophysik GmbH; Leipzig: Germany). The incremental exercise test protocol commenced at 5 km/h and 1% 
gradient with a ramped increase in gradient to 25% over 18 min. If 25% was reached, treadmill speed was 
increased by 0.66 km/h/min. Sense of effort during exercise (Rating of Perceived Exertion; RPE) was recorded 
each minute of the test using the Borg CR100 (9). V̇O2max was identified if all of the following criteria were met: 
volitional fatigue; a plateau in oxygen consumption (V̇O2) despite an increase in workload; respiratory exchange 
ratio (RER) ≥ 1.15. Participants also completed the same maximal exercise protocol in hypoxia (FIO2 = 0.141, 
equivalent 3225 m), with the two tests separated by a minimum of 48 h.  
 
Six-hour hypoxic exposure 
On day five of each supplementation period, participants completed a six-hour poikilocapnic hypoxic exposure in 
a normobaric hypoxic chamber (FIO2 = 0.124; equivalent 4219 m: Hypoxico, Inc. New York, NY). After fifteen 
min seated rest, participants completed the first of three 20-min bouts of submaximal exercise at 40% hypoxic 
V̇O2max reserve. The submaximal exercise protocol during the 6 h exposure consisted of exercise bout one, 
completed between 15-35 min; exercise bout two, 140-160 min; and exercise bout three, 300-320 min. Blood 
pressure and heart rate measured by a stress BP system (Tango+; SunTech Medical, Inc., Morrisville, NC; USA), 
and oxygen saturation (SpO2) measured by pulse oximetry (9550 OnyxII; Nonin Medical Inc, Minnesota), were 
assessed every hour and pre- and post-each exercise bout throughout the 6 h exposure. Mean arterial blood 
pressure (MAP) was calculated to account for heart rate using the equation provided by Moran and colleagues 
(36): 
MAP = DBP + ((0.01 × exp(4.14 – 40.74 ÷ HR)) × (SBP – DBP)) 
Where MAP, Mean arterial blood pressure; DBP, Diastolic blood pressure; HR, Heart rate; SBP, Systolic blood 
pressure. 
 
High-altitude headache and AMS 
High-altitude headache was assessed every hour and pre- and post-each exercise bout throughout the six-hour 
exposure on day five of supplementation, using a 0-100 mm visual analogue scale (VAS) (23). Participants were 
asked to mark on the line the intensity/feeling that corresponded to their headache, where the beginning of the line 
indicated no perception/feeling at all and the end of the line indicated maximum perception/feeling. AMS was 
assessed by the Acute Cerebral Mountain Sickness (AMS-C) score calculated from the 11-item Environmental 
Symptoms Questionnaire (ESQ) (41). Participants rated the severity of each item from one to five, and the ratings 
were multiplied by their factorial loadings and summed. In order to investigate whether any effects of nitrate 
supplementation were affected by the presence or absence of AMS, participants were split into two groups 
depending on whether they had AMS on placebo. Participants with AMS-C < 0.7 in both trials were classified as 
AMS-, while participants with AMS-C ≥ 0.7 on placebo were classified as AMS+ (40). Participants with AMS-
C < 0.7 on placebo, but AMS-C ≥ 0.7 on nitrate were included in the whole sample analyses, but were not included 
in AMS+/- sub-analyses. 
 
Submaximal exercise responses 
Sense of effort during the three submaximal exercise bouts was assessed by RPE. RPE was recorded using the 
Borg CR100 (9) which asks participants to rate the intensity of the exercise sensation using numbers from 0-100+ 
and verbal descriptors (e.g. “moderate”, equivalent to 25). Extensive evidence supports the use of RPE as a valid 
and appropriate method to record sense of effort and perceptual responses to exercise (13). RPE, heart rate and 
SpO2 were recorded at two-min intervals during the three exercise bouts. In addition to these variables, the study 
design targeted exercise bout two to examine extra physiological responses, including ventilatory parameters and 
exercising blood pressure, in an attempt to identify possible mechanisms of nitrate’s effect on exercise and AMS 
before AMS was present. We did not collect this data during exercise bout one because this bout occurred too 
early, when variable responses such as the hypoxic ventilatory response (47) would likely mask any mechanistic 
physiological changes. We did not collect this data during exercise bout three because this bout occurred too late, 
when AMS was already present. To be consistent with a cause and effect relationship, any physiological changes 
must be observed before the onset of AMS; at exercise bout three it would not be possible to differentiate between 
cause and consequence of AMS. Thus, during exercise bout two exercising blood pressure was recorded every 
two min and ventilation (VE), V̇O2, RER, and end-tidal carbon dioxide (PETCO2) were measured using online gas 
analysis. To account for the hypoxic conditions, the gas analyzer was calibrated using ambient air (12.4% O2; 
0.03% CO2) and a FiO2–specific calibration gas (8% O2; 5% CO2; Industrial Gases, BOC ltd, Surrey, UK). 
 
Exercise performance (time to exhaustion; TTE) 
On day six of each supplementation period, participants completed a time to exhaustion (TTE) test at 5 km/h and 
a gradient corresponding to 80% of their hypoxic V̇O2max reserve in acute hypoxia (FIO2 = 0.141, equivalent 3225 
m). Exercise performance was defined as TTE determined by the time from onset of test to task failure (volitional 
exhaustion or inability to maintain treadmill speed). During the exercise test SpO2, heart rate, and RPE were 
recorded each minute. Participants were blind to time elapsed and provided no verbal encouragement.  
 
Plasma nitric oxide metabolites (NOx) 
All glassware, utensils, and surfaces were rinsed with deionised water to remove residue NO3- and NO2- before 
blood analysis. After thawing at room temperature, plasma samples were initially deproteinized using cold ethanol 
precipitation. Initially 0.5 mL of sample was placed in a chilled microcentrifuge tube, along with 1 mL of cold 
(0°C) ethanol; then the samples were vortexed and left to stand at 0°C for 30 min. Thereafter, samples were 
centrifuged at 14,000 rpm for 5 min, and the supernatant removed for subsequent analysis. NOx (nitrate + nitrite) 
in the deproteinized plasma samples was reduced to NO in the presence of 0.8% (w/v) vanadium trichloride in 1 
M hydrochloric acid. The production of NO was detected by a Sievers gas-phase chemiluminescence NO analyser 
(Sievers NOA 280i; Analytix, Duham, UK) and the NOx concentration was derived by plotting signal (mV) area 
against a calibration plot of 1-750 µM sodium NO3-.   
 Statistical analyses 
Differences between nitrate and placebo were determined by confidence intervals relating to a priori meaningful 
differences (22), supported by statistical differences testing by repeated measures analysis of variance (RM 
ANOVA) or t-tests as appropriate (p < 0.05). For the primary analysis, (to determine the effect of dietary nitrate 
supplementation on high-altitude headache) a 2 × 4 (Trial × Time) RM ANOVA was used to compare high-
altitude headache severity by VAS from 4 to 6 h between nitrate and placebo trials. The time course of 4 to 6 h 
was chosen for the primary analysis based on the expected time that AMS would develop from previous data from 
our laboratory at a similar FiO2 (28–30) that showed no incidence of AMS before 4 h, but an AMS incidence of 
50% after 6 h. A sample size estimation for the primary analysis indicated that 16 participants were needed to 
produce an 80% chance of obtaining statistical significance at the 0.05 level for a two-tailed design (45), based 
on a minimum important difference of 10 mm (23), a standard deviation of the difference of 18 mm, and an 
estimated average correlation of 0.4 (data from (29)). To determine the influence of AMS, all analyses were 
repeated including a factor for AMS presence or absence (AMS+ or AMS-), and interpreted on the basis of 
significant interactions. 
 
The effect of nitrate supplementation on exercise performance (TTE) was determined by paired samples t-test. A 
sample size estimation for this analysis indicated that 12 participants were needed to produce an 80% chance of 
obtaining statistical significance at the 0.05 level for a two-tailed design (8), based on a minimum important 
difference of 30 s, and a standard deviation of the difference of 33 s (data from (33)). To determine the effect of 
nitrate supplementation on i) RPE, ii) SpO2, and ii) heart rate, a 2 × 5 (Trial × Isotime) RM ANOVA was used to 
compare nitrate and placebo trials at 0%, 25%, 50%, 75%, and 100% of isotime during the TTE test. Resting 
values taken immediately before commencing the TTE were recorded as 0% isotime. 100% isotime was defined 
as the last complete minute of the shortest TTE, and the corresponding minute in the longest TTE for each 
participant. The minute identified as 100% isotime was multiplied by 0.25, 0.5, and 0.75 and rounded to the 
nearest complete minute to give 25% isotime, 50% isotime, and 75% isotime, respectively. 
 
Five participants did not complete the TTE on day six due to injury or technical reasons, e.g. cramp or tripping 
whilst on the treadmill, and one of these was also removed from analyses relating to RPE on day five due to failure 
to use the RPE scale consistently. All analyses were completed using SPSS version 23 (IBM Corp, Armonk; NY).  
RESULTS 
Participants were sufficiently blinded to the intervention since the manipulation check indicated participants 
guessed correctly in only 18% of trials, guessed incorrectly in 34% of trials, and were unable to distinguish 
between interventions in 48% of trials.  
 
Plasma nitric oxide metabolites (NOx) 
Subject compliance with the supplementation protocol was 100%. This self-reported compliance measure was 
confirmed by plasma NOx data. Plasma NOx was similar between trials at baseline (nitrate = 27 (9); placebo = 28 
(9); [-5, 3] μM; p = 0.7). The nitrate supplementation effectively altered plasma NOx concentrations. Compared 
to placebo, nitrate supplementation increased plasma NOx on day five (mean diff [95%CI]: ∆182 [155, 208] µM; 
p < 0.001). Compared to placebo, nitrate supplementation also increased plasma NOx on day six in the 15 
participants that completed the time to exhaustion tests (∆244 [201, 286] µM; p < 0.001). By design, plasma NOx 
was not altered compared to baseline, with five (∆-3 [-8, 2] µM; p = 0.3) or six (∆-3 [-10, 1] μM; p = 0.2) days of 
placebo supplementation. 
 
High-altitude headache and AMS 
There was no headache at 0 h (pre-hypoxia) in either trial (nitrate = 1 (4); placebo = 4 (9); [-7, 2] mm; p = 0.2). 
Although headache tended to increase after exercise bout one (∆4 [-1, 9] mm; p = 0.08) and bout two (∆8 [0, 15] 
mm; p = 0.05), there was no effect of nitrate (both p ≥ 0.4; Figure 2A). As expected, AMS and headache increased 
in the latter part of the trial (p < 0.05). Unexpectedly this effect was exacerbated by nitrate. From 4 to 6 h, nitrate 
increased headache severity compared to placebo (∆10 [1, 20] mm; p = 0.03) and tended to increase AMS-C 
compared to placebo (∆0.15 [-0.01, 0.31]; p = 0.07; Figure 2B). 
 
Physiological responses to 6 h hypoxia 
Resting physiological responses (heart rate, SpO2, and blood pressure) changed throughout the 6 h exposure, but 
were not affected by nitrate. Heart rate increased over the hypoxic exposure (∆16 [11, 21] bpm; p < 0.001), and 
after each exercise bout, but was not affected by nitrate (∆-2 [-5, 2] bpm; p = 0.4). SpO2 decreased over the 
hypoxic exposure (∆-14 [-17, -11] %; p < 0.001), and after each exercise bout, but was not affected by nitrate (∆0 
[-1, 1] %; p = 0.8). Nitrate supplementation had no effect on any measure of resting blood pressure, with no 
difference in systolic blood pressure (SBP; ∆1 [-4, 5] mmHg; p = 0.7), diastolic blood pressure (DBP; ∆-1 [-4, 2] 
mmHg; p = 0.4), or mean arterial blood pressure (MAP; ∆1 [-3, 4] mmHg; p = 0.8). 
 
Submaximal exercise responses 
Dietary nitrate increased sense of effort compared to placebo during submaximal exercise in 6 h hypoxia (Figure 
3A). Nitrate elicited a small but significant increase in RPE for exercise bout one (∆4 [0, 8]; p = 0.03), and a larger 
increase for exercise bout three (∆7 [-1, 14]; p = 0.07), although had no effect on RPE for exercise bout two (∆2 
[-5, 9]; p = 0.5). In the nitrate trial, headache at 5 h (pre-exercise bout three) was positively correlated with change 
in RPE from exercise bout one to exercise bout three (r = 0.67; p < 0.01). When analyzed across the whole sample, 
nitrate had no effect on any physiological response to the three submaximal exercise bouts (Table 1). 
 
Influence of AMS presence or absence (AMS+/-) 
Twelve participants were classified as AMS- and five were AMS+ (see Methods: High-altitude headache and 
AMS). There were no differences in baseline characteristics or NOx concentrations at any point between AMS+ 
and AMS- (all p > 0.5; data not shown).  
 
In AMS-, nitrate had no effect on high-altitude headache (∆2 [-5, 9] mm; p = 0.6; Figure 2C) or AMS-C (∆-0.04 
[-0.13, 0.06]; p = 0.4; Figure 2D). In AMS+, nitrate increased altitude illness severity from 4 h: in AMS+, high-
altitude headache severity was more than doubled with nitrate compared to placebo (∆26 [-3, 56] mm; p = 0.07; 
Figure 2E) and AMS-C was similarly increased (Δ0.46 [-0.10, 1.02]; p = 0.09; Figure 2F). In AMS-, there was no 
difference in RPE between nitrate and placebo for any of the exercise bouts (Figure 3C). In AMS+, by the end of 
the exposure, dietary nitrate had increased sense of effort during submaximal exercise compared to placebo 
(Figure 3E; ∆14 [1, 28]; p = 0.04).  
 
Depending on whether participants were AMS- or AMS+, nitrate had opposite effects on physiological responses 
to submaximal exercise during the hypoxic exposure (determined by significant AMS-trial interactions). During 
exercise bout two, in AMS-, nitrate decreased ventilation in comparison to placebo (-3.0 [-5.5, -0.4] L/min; p = 
0.03; Figure 4A), and had no effect on V̇O2 (∆-0.02 [-0.13, 0.09] L/min; p = 0.6; Figure 5A) or MAP (∆-1 [-9, 6] 
mmHg; p = 0.7; Figure 6A). In contrast, in AMS+, nitrate increased ventilation (∆ 3.1 [-0.7, 7.0] L/min; p = 0.1; 
Figure 4B), V̇O2 (∆0.10 [0.03, 0.17] L/min; p = 0.02; Figure 5B), and MAP (∆7 [-3, 17] mmHg; p = 0.1; Figure 
6B). During exercise bout three, in AMS- nitrate increased SpO2 compared to placebo from 12 min onwards (∆ 3 
[0, 4] %; p = 0.03; Figure 3D). However, in AMS+, nitrate had no effect on SpO2 for any exercise bout (Figure 
3F). The effect of nitrate on PETCO2 was not altered depending on the presence or absence of AMS (AMS-trial 
interaction; p = 0.2). 
 
Exercise performance (time to exhaustion; TTE) 
Six days dietary nitrate supplementation had no effect on TTE in hypoxia (∆10 [-103, 123] s; p = 0.9). Dietary 
nitrate supplementation had no effect on heart rate, SpO2, or RPE at any isotime, or at exhaustion (Table 2). 
 
Whether participants experienced AMS did not influence the effect of nitrate on exercise performance (TTE; 
group-trial interaction; p = 0.9). Specifically, nitrate had no effect on TTE in AMS- (∆16 [-115, 148] s; p = 0.8) 
or in AMS+ (∆10 [-103, 123] s; p = 0.9).  
DISCUSSION 
The primary findings of this study were that dietary nitrate supplementation did not reduce AMS severity, 
specifically high-altitude headache, or improve exercise performance in hypoxia. When assessed over the whole 
sample, nitrate had no effect on any physiological response to hypoxia. However, opposing effects of nitrate were 
observed in those with and without AMS. In participants who did not develop AMS (AMS-), nitrate decreased 
ventilation and improved SpO2 during exercise but this did not translate into reduced AMS symptoms or an 
improvement in exercise performance. In contrast, in AMS+, nitrate increased ventilation and O2 cost of exercise, 
headache and AMS severity, and sense of effort during submaximal exercise in 6 h hypoxia.  
 
The increase in headache and AMS that occurred in the latter part of the trial was exacerbated by nitrate. It is clear 
this was not due to nitrate increasing exercise-induced headache, since there was no effect of nitrate on headache 
post exercise bout one or two that occurred earlier in the hypoxic exposure, before AMS was present. In those 
that developed AMS dietary nitrate induced a 26 mm increase in headache, which is of sufficient magnitude to 
have clinical relevance (23). This finding is in agreement with a previous study that reported greater headache at 
altitude after L-arginine supplementation (32). However it contrasts the null finding reported by Hennis and 
colleagues in the field (20); the only previous study to investigate the effects of chronic dietary nitrate 
supplementation on AMS. This difference in results is most likely due to differences in study design. Specifically, 
in Hennis and colleagues’ study (20) biochemical confirmation of the nitrate supplementation was not performed 
and therefore it was not possible to determine if the nitrate supplementation was effective. This is of particular 
concern since the authors reported poor compliance. Further, as AMS is determined by subjective responses, the 
use of a non-taste matched placebo means placebo or nocebo effects cannot be dismissed. In contrast, we 
completed a double-blind placebo-controlled study, and report 100% compliance to the supplementation protocol, 
with confirmation of successful blinding and increased plasma NOx in the nitrate trial.  
 
When activated in the brain, NO directly stimulates the trigeminovascular system, responsible for headache pain 
sensation (3). In addition, an increase in cerebral blood flow and resultant increase in intracranial pressure can 
also result in trigeminovascular system activation, and is suggested to cause high-altitude headache and AMS 
(27). Therefore increasing the bioavailability of NO through dietary nitrate supplementation is likely to directly 
stimulate trigeminovascular afferents, and concurrently elevate hypoxia-induced cerebral vasodilation. This 
provides a possible mechanism for the increase in high-altitude headache and AMS observed herein. Further 
support for this explanation is provided by previous studies that have utilized NO-synthase inhibitors (e.g. L-
NMMA) (3) and artificial vasoconstriction (25) to successfully reverse headache. 
 
Nitrate supplementation did not benefit exercise performance as assessed by time to exhaustion in acute hypoxia. 
This finding is in agreement with the only previous randomized controlled trial (RCT) to assess exercise 
performance in acute hypoxia (< 2 h) following six days dietary nitrate supplementation (10). Bourdillon et al. 
(10) found dietary nitrate supplementation did not alter hypoxic pulmonary vasoconstriction or 15 km time trial 
performance in acute hypoxia (FIO2 = 0.11). A further novel approach of the current study was to examine exercise 
responses during 6 h hypoxic exposure after dietary nitrate supplementation. Contrary to our hypothesis, nitrate 
did not improve submaximal exercise performance even in AMS- where nitrate improved SpO2 during exercise 
(3% after 5 h in hypoxia). Further, in those that developed AMS+, nitrate actually impaired exercise by increasing 
sense of effort; participants had to invest more effort to achieve the same exercise output in the nitrate trial, 
compared to placebo. In those that developed AMS (AMS+), nitrate also increased the O2 cost of fixed workload 
exercise, which may have been driven by an increase in ventilation. Increased ventilation is associated with greater 
respiratory muscle demand and dyspnea (1), which are important contributing factors of sense of effort (7). As 
exercising sense of effort, ventilation, and O2 cost of exercise were increased and present before AMS, nitrate 
should be considered the cause of the negative effects observed in AMS+, rather than an effect of AMS symptoms. 
In addition, the elevated AMS symptoms may have contributed to the increase in sense of effort in the final bout 
of exercise, as the increase in sense of effort was proportional to headache severity immediately before exercise. 
By the end of the final exercise bout sense of effort was increased by 54% in those who experienced AMS, 
equivalent to an entire verbal descriptor (from “moderate”, to “somewhat strong”). Since the exercise typically 
completed at altitude is often long-duration and submaximal, this finding has great importance for those travelling 
to altitude for work and recreation as increased sense of effort is associated with poorer mood, and increased 
fatigue (39), which is an important risk factor at altitude (15). 
 
This study is limited by the absence of a direct measure of cerebral blood flow to support the proposed mechanistic 
interpretation. However, the conclusion of cause and effect is supported by the use of a strong experimental design, 
and a theoretical explanation backed by a wealth of existing literature (27). This study was also limited by the 
duration of exposure (6 h), and is therefore unable to conclude the effects of nitrate on physiological and perceptual 
responses with more chronic exposure to altitude, for example over many days or weeks. Another limitation of 
this study is that all participants were men, and thus the findings may not be applicable to women. In addition, the 
study design did not allow separation of the effects of nitrate in hypoxia per se from any interaction with exercise, 
although the effects of nitrate supplementation with exercise in normoxia have been studied in detail in previous 
literature (34). 
 
In conclusion, dietary nitrate increases AMS symptom severity, specifically headache, and sense of effort during 
submaximal exercise, particularly in those who experience AMS. Therefore, dietary nitrate is not recommended 
as an AMS prophylactic or ergogenic aid in non-acclimatized individuals at altitude. 
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Figure 1. Overview of trial protocol. Supplementation was taken at the same time each day, 2.5 h before any 
exercise tests. Participants completed a 6 h exposure to hypoxia on day five, and an acute hypoxic exercise to 
exhaustion test on day six. All exercise intensities are set at a proportion of hypoxic V̇O2max reserve. Additional 
physiological data was obtained by online gas analysis and a stress blood pressure system during exercise bout 
two. Filled black arrows indicate headache and AMS data included in the primary analysis. 
  
  
Figure 2. High-altitude headache and AMS during 6 h in hypoxia (FIO2 = 0.124) on day five. Grey shaded 
bars indicate submaximal exercise bouts (40% V̇O2max reserve). From 4 to 6 h, in the whole sample, nitrate 
increased headache by visual analogue scale (VAS; Panel A), and tended to increase AMS-C score calculated 
from the Environmental Symptoms Questionnaire (Panel B). In AMS- (participants with AMS-C score < 0.7 in 
both trials) dietary nitrate had no effect on headache (Panel C), or AMS-C (Panel D). In AMS+ (participants with 
AMS-C ≥ 0.7 on placebo), nitrate increased headache (Panel E) and AMS-C (Panel F). *nitrate significantly 
higher than placebo (p < 0.05). 
  
 Figure 3. Sense of effort (RPE) and oxygen saturation (SpO2) during submaximal exercise. In the whole 
sample, dietary nitrate increased RPE (Panel A), but had no effect on SpO2 (Panel B). In AMS- (participants with 
AMS-C score < 0.7 in both trials), dietary nitrate had no effect on RPE (Panel C), but increased SpO2 during 
exercise bout three (Panel D). In AMS+ (participants with AMS-C ≥ 0.7 on placebo), dietary nitrate increased 
RPE (Panel E), but had no effect on SpO2 (Panel F). *nitrate significantly higher than placebo (p < 0.05). 
  
 Figure 4. Ventilation during submaximal exercise (exercise bout two). Dietary nitrate decreased ventilation 
during exercise bout two in AMS- (participants with AMS-C score < 0.7 in both trials; Panel A), and increased 
ventilation in AMS+ (participants with AMS-C ≥ 0.7 on placebo; Panel B). *nitrate significantly higher than 
placebo (p < 0.05). 
  
 Figure 5. Oxygen cost (V̇O2) of submaximal exercise (exercise bout two). Dietary nitrate had no effect on V̇O2 
during exercise bout two in AMS- (participants with AMS-C score < 0.7 in both trials; Panel A), but increased 
V̇O2 in AMS+ (participants with AMS-C ≥ 0.7 on placebo; Panel B). *nitrate significantly higher than placebo (p 
< 0.05). 
  
 Figure 6. Mean arterial pressure (MAP) during submaximal exercise (exercise bout two).  Dietary nitrate 
had no effect on MAP during exercise bout two in AMS- (participants with AMS-C score < 0.7 in both trials; 
Panel A), but increased MAP in AMS+ (participants with AMS-C ≥ 0.7 on placebo; Panel B). Nitrate significantly 
higher than placebo (*p < 0.05; **p < 0.01). 
  
 TABLE 1. Physiological responses to submaximal exercise in hypoxia. All data are end-exercise and presented 
as mean (SD). LB, Lower Bound; UB, Upper Bound; SpO2, Oxygen saturation; V̇O2, Oxygen consumption, VE, 
Ventilation; RER, Respiratory exchange ratio; PETCO2, End-tidal carbon dioxide; SBP, Systolic blood pressure; 
DBP, Diastolic blood pressure; MAP, Mean arterial blood pressure. N = 20. 
  
 
 Nitrate Placebo 
95% CI diff 
p 
LB UB 
Exercise bout one  
 Heart rate (bpm) 129 (21) 133 (17) -12 2 0.2 
 SpO2 (%) 76 (3) 76 (3) -1 1 0.8 
Exercise bout two  
 Heart rate (bpm) 138 (20) 136 (20) -6 10 0.6 
 SpO2 (%) 75 (4) 75 (4) -1 1 0.7 
 V̇O2 (L·min-1) 1.70 (0.30) 1.69 (0.29) -0.07 0.10 0.7 
 VE (L·min-1) 59.3 (11.7) 59.9 (12.7) -4.5 3.2 0.7 
 RER 0.97 (0.08) 0.97 (0.08) -0.02 0.04 0.6 
 PETCO2 (mmHg) 32.6 (3.3) 32.1 (2.8) -0.3 1.3 0.2 
 SBP (mmHg) 179 (17) 166 (25) -1 27 0.06 
 DBP (mmHg) 58 (9) 60 (11) -9 5 0.5 
 MAP (mmHg) 113 (8) 110 (16) -4 11 0.3 
Exercise bout three  
 Heart rate (bpm) 139 (23) 140 (24) -12 10 0.8 
 SpO2 (%) 76 (4) 75 (4) -1 2 0.3 
 TABLE 2. Heart rate, SpO2, and RPE during the time to exhaustion (TTE) tests. Data are presented as mean 
(SD). Dietary nitrate supplementation had no effect on heart rate, SpO2, or RPE at any isotime, or at exhaustion. 
SpO2, Oxygen saturation; RPE, Rating of perceived exertion. †Main effect for time (p < 0.05). N = 15. 
 
 
  Isotime 
Exhaustion 
  0% 25% 50% 75% 100% 
Heart rate (bpm) 
 Placebo 84 (10) 145 (24) 153 (33) 161 (27) 172 (26) 168 (34)† 
 Nitrate 88 (11) 149 (17) 157 (27) 168 (18) 168 (24) 171 (22)† 
SpO2 (%) 
 Placebo 89 (3) 85 (5) 82 (4) 81 (3) 81 (4) 81 (4)† 
 Nitrate 89 (4) 84 (3) 81 (5) 81 (2) 81 (4) 82 (4)† 
RPE (CR100) 
 Placebo 2 (2) 24 (13) 49 (15) 76 (15) 96 (10) 102 (8)† 
 Nitrate 2 (2) 21 (11) 49 (15) 73 (15) 94 (13) 102 (11)† 
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